- 1 Pharmaceutical Payments to Japanese Board-Certified Infectious Disease
- 2 Specialists: A Four-year Retrospective Analysis of Payments from 92
- 3 Pharmaceutical Companies between 2016 and 2019
- 5 Authors:

10

- 6 Anju Murayama<sup>1,2,\*,†</sup>; Sae Kamamoto<sup>1,3</sup>; Kohki Yamada<sup>1</sup>; Divya Bhandari, MSH<sup>1</sup>; Iori
- 7 Shoji<sup>1</sup>; Hanano Mamada<sup>1</sup>; Moe Kawashima<sup>1</sup>; Erika Yamashita<sup>1</sup>; Hiroaki Saito, MD,
- 8 PhD<sup>4</sup>; Eiji Kusumi, MD<sup>5</sup>; Toyoaki Sawano, MD, PhD<sup>6</sup>; Binaya Sapkota<sup>7</sup>; Tetsuya
- 9 Tanimoto, MD<sup>1,8</sup>; Akihiko Ozaki, MD, PhD<sup>1,9</sup>
- 11 **Affiliations:**
- <sup>1</sup>Medical Governance Research Institute, Minato-ku, Tokyo, Japan
- <sup>2</sup>Tohoku University School of Medicine, Sendai city, Miyagi, Japan
- <sup>3</sup>Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
- <sup>4</sup>Department of Gastroenterology, Sendai Kosei Hospital, Sendai City, Miyagi, Japan
- 16 <sup>5</sup>Navitas Clinic Shinjuku, Shinjuku-ku, Tokyo, Japan
- 17 <sup>6</sup>Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City, Fukushima,
- 18 Japan

<sup>7</sup>Nobel College Faculty of Health Sciences, affiliated to Pokhara University, Kathmandu, 19 20 Nepal <sup>8</sup>Department of Internal Medicine, Navitas Clinic, Tachikawa City, Tokyo, Japan 21 22 Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City, 23 Fukushima, Japan 24 25 Correspondence 26 Anju Murayama 27 Medical Governance Research Institute, Minato-ku, Tokyo, 1087505, Japan 28 Telephone: 81-90-6321-6996 29 Email address: <a href="mailto:ange21tera@gmail.com">ange21tera@gmail.com</a> 30 **Conflicts of interest:** 31 32 Dr. Saito received personal fees from TAIHO Pharmaceutical Co. Ltd outside the scope 33 of the submitted work. Dr. Kusumi received personal fees from Otsuka Pharmaceutical 34 outside the scope of the submitted work. Drs. Ozaki and Tanimoto received personal 35 fees from Medical Network Systems outside the scope of the submitted work. Dr. 36 Tanimoto also received personal fees from Bionics Co. Ltd, outside the scope of the

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

submitted work. Regarding non-financial conflicts of interest among the study authors, all are engaged in ongoing research examining financial and non-financial conflicts of interest among healthcare professionals and pharmaceutical companies in Japan. Individually, Anju Murayama, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, and Akihiko Ozaki have contributed to several published studies addressing conflicts of interest and quality of evidence among clinical practice guideline authors in Japan and the United States. The other authors have no example of conflicts of interest to disclose. **Funding sources:** This study was funded in part by the Medical Governance Research Institute. This nonprofit enterprise receives donations from Ain Pharmacies, Inc., a dispensing pharmacy, other organizations, and private individuals. This study also received support from the Tansa (formerly known as the Waseda Chronicle), an independent non-profit news organization dedicated to investigative journalism. None of the entities providing financial support for this study contributed to the design, execution, data analyses, or interpretation of study findings and the drafting of this manuscript.

56 Abstract 57 **Objective** Conflict of interest with pharmaceutical companies is one of the most contentious issues 58 59 in infectious diseases. However, there is a lack of whole picture of detailed payments in 60 Japan. 61 62 **Study Design and Setting** 63 This retrospective study assessed financial relationships between pharmaceutical 64 companies and all infectious disease specialists board-certified by the Japanese 65 Association for Infectious Disease, using publicly disclosed payment data from 92 66 pharmaceutical companies. Descriptive analyses were conducted for the payments. 67 Payment trends were examined by the generalized estimating equations. 68 **Results** 69 70 Of 1614 board-certified infection disease specialists, 1,055 (65.4%) received a total of 71 \$17,784,070 payments, corresponding to 21,680 cases between 2016 and 2019. The 72 mean±SD and median (interquartile range: IQR) were \$16,857±\$45,010 and \$3,183 73 (\$938□\$11,250) in payments. All board executive members of Japanese Association of

- 74 Infectious Disease received higher payments averaging \$163,792. There were no
- 75 significant changes in payments per specialist (annual change rate: -1.4% [95% CI: -
- 76  $4.7 \square 2.3\%$ , p=0.48) and prevalence of specialists with payments (annual change rate: -
- 77 1.4% [95% CI:  $-3.1\% \square 0.2\%$ ], p=0.093) over the four years.

## Conclusion

78

79

- 80 There were substantial financial relationships between pharmaceutical companies and
- 81 board-certified infectious disease specialists in Japan. Such personal payments must be
- 82 restricted to a certain level to avoid potential conflict of interest.

83	Keywords:
84	Board-Certified Infectious Disease Specialists, Pharmaceutical payments, Physician
85	payment, conflicts of interest, Health policy, Japan
86	
87	Running title: Pharmaceutical Payments to Japanese Board-Certified Infectious
88	Disease Specialists
89	
90	Word count: Abstract 197 words, Main text 3432 words
91	

Main text

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

Introduction There has been an increasing concern on financial relationships between healthcare professionals, healthcare organizations and pharmaceutical companies, which sometimes become conflicts of interest (COI), because of its potential bias on healthcare. In response to this concern, many countries have started requesting pharmaceutical companies to disclose data on their donations and honoraria to healthcare professionals and healthcare organizations.[1, 2] Consequently, previous studies utilizing these data have demonstrated that there were substantial financial relationships between pharmaceutical companies.[3-7] Among several specialties, infectious disease is one where there is a greatest concern about the influence from pharmaceutical companies. As in the case of Lyme disease guideline issued by the Infectious Diseases Society of America (IDSA), the guideline chair and authors manipulated the guideline recommendations and statements for the benefits of testing and insurance companies, leading to inadmissible harms on the patients in the US.[8]

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

In cases of Japan, 91.7% of authors of clinical guideline for methicillin-resistant Staphylococcus aureus issued by the Japanese Association for Infectious Diseases received an average of \$28,371 personal payments in 2016, and four pharmaceutical companies' employees were involved in the guideline development.[9] Moreover, during coronavirus disease 2019 (COVID-19) pandemic, substantial financial relationships were uncovered among healthcare professionals specialized in infectious diseases and pharmaceutical companies worldwide. However, the Japanese government COVID-19 advisory board members did not manage to disclose the detailed information on COI with pharmaceutical companies.[10] Although COI among influential infectious disease experts such as television commentators specialized in infectious diseases[11], guideline authors[7, 9], and government advisory members[10] were investigated, the whole picture of financial relationships with pharmaceutical companies remains to be elucidated. Since board-certified infectious disease specialists directly prescribe drugs for patients, it is crucial to understand financial relationships among pharmaceutical companies and those specialists. This study aimed to elucidate the prevalence of board-certified infectious disease specialists receiving payment from pharmaceutical companies, the magnitude of the

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

payments, and payments trend over last few years in Japan. Methods Study design and participants This study was a retrospective analysis evaluating financial relationships among all board-certified infectious disease specialists and pharmaceutical companies in Japan. All infectious disease specialists who were board-certified by the Japanese Association for Infectious Disease (the Association hereafter) as of November 2021 were included in this study. The Association is the largest and most prestigious professional medical society for infectious diseases in Japan, which contributed to improve patient care by promoting research and training physicians for infectious diseases in Japan since its establishment in 1926. Also, the Association is the only organization in Japan that trains and certifies infectious diseases specialists in the country. As of November 2021, the Association required physicians to complete several requirements to certificate them as infectious disease specialists, such as being a specialist certified by at least one of the 19 major Japanese medical societies[12], having completed at least six years of clinical practice training after having acquired a

medical license and at least three years of specialized training in infectious diseases at

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

an institution accredited by the Association, and having published at least one academic article on a peer-review journal and at least two conference presentations as the first author. Data collection Data concerning name and affiliations for all of those board-certified specialists were extracted from the official webpage of the Association (https://www.kansensho.or.jp/modules/senmoni/index.php?content\_id=29) on November 10, 2021. Also, the Association webpage provided us names of all executive board members as of 2021. All drugs with additional or new indications for infectious diseases between 2015 and 2019 were extracted from the database of the Pharmaceuticals and Medical Devices Agency[13], the Japanese regulatory authority for drugs and medical devices. Payment data from 2016 to 2019 to all healthcare professionals and healthcare organizations for lecturing, writing, and consulting were collected from all 92 pharmaceutical companies affiliated with Japan Pharmaceutical Manufacturers Association (JPMA).[14-16] JPMA required that the member companies disclose only

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

the payment for lecturing, writing, and consulting on the individual basis. However, payment categories such as meals, travel, and accommodations were not disclosed on each individual specialist. Thus, we could only analyze personal payments concerning lecturing, writing, and consulting. Then, we stored all payment data collected from 92 companies into an excel file and structured the searchable payment database. By searching for the specialist names in the payment database, the payment data to the infectious disease specialists were extracted from the payment database. The extracted data included recipient names, recipient affiliations, monetary amount, number of payment cases, payment category, and name of pharmaceutical company making the payment. To remove payment data of different persons with duplicate names in the database, we checked and compared the affiliations, affiliation address, and recipient specialties among the data from the Association and the pharmaceutical companies. In cases where affiliation reported by the company differed from the one reported by the Association, we manually googled the name of specialists and collected other data from the official institutional webpages and other sources to verify that they were the same person. The detailed process can be found in our previously published papers.[5, 14-16]

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

Data Analysis Descriptive analyses were performed for payment values and number of cases on individual specialist and pharmaceutical company levels. Average and median payments, cases, number of companies making payments per specialist were calculated based on the only specialists receiving payment in each year, as in other studies assessing pharmaceutical payments to physicians.[17-20] To compare the payments among the specialists with and without a leading role in the Association, the average mean and median payments were evaluated by the specialists with and without the executive board membership. The difference between two groups was assessed by the Mann-Whitney U test, as the payments data were not normally distributed. The Gini index and the shares of the payment values held by the top 1%, 5%, 10%, and 25% of the specialists were calculated to examine distribution and concentration of payments. The Gini index ranges from 0 to 1, and the greater the Gini index is, the greater the disparity in the distribution of payments on the specialist basis, as performed previously.[14, 21, 22] Also payment distributions were geographically examined on prefectures and regions, as there were differences in number of the specialists and the

medical institutions accredited by the Association.

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

The population-averaged generalized estimating equations (GEE) were performed to evaluate the payment trends. As the payment distribution was highly skewed (Supplemental Material 1), negative binomial GEE model for the payment values per specialist, and linear GEE log-linked model with binomial distribution for the prevalence of specialists with payments were used. The year of payments was set as independent variable, and the payment values per specialist and proportion of physicians receiving payments were set as dependent variables. The average annual changes in independent variables, payment values per specialist and prevalence of specialists with one or more payments, were reported as a relative percentage. As several pharmaceutical companies among all 92 companies disaffiliated from the JPMA and newly joined the JPMA, there were 18 companies without payment data over the four years. Thus, the average and median payments for each year and the trend of payments were calculated based on payments from all 92 companies and 74 companies with payment data for the four years between 2016 and 2019, as previously described. [3, 4, 23] Finally, we assessed association between number of drugs with new or additional indications and (1) total payments and (2) number of specialists with payments on company level using the Spearman's correlation.

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

Japanese ven (¥) was converted into US dollars (\$) using 2019 average monthly exchange rates of ¥109.0 per \$1. All analyses were conducted using Microsoft Excel, version 16.0 (Microsoft Corp.) and Stata version 15 (StataCorp.). **Ethical approval** The Ethics Committee of the Medical Governance Research Institute approved this study (approval number: MG2018-04-20200605; approval date: June 5, 2020). As this study was a retrospective analysis of the publicly available information, informed consent was waived by the Ethics Committee. **Results** We identified 1,614 infectious disease specialists certified by the Association as of November 10, 2021. The Association stated that there were a total of 1,622 infectious disease specialists in Japan, and therefore, names of eight specialists missing were not disclosed on the webpage, as the specialists could have wished not to disclose their names on the webpage. Overview and Per-Specialist Payments

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

Of 1,614 eligible board-certified infectious disease specialists, 1,055 (65.4%) received one or more payments, totaling \$17,784,070 corresponding to 21,680 payment counts between 2016 and 2019. Among 92 companies, 78 (84.8%) made at least one payment to the specialists over the four-year period. The average (standard deviation: SD) and median (interquartile range: IQR) were \$16,857 (\$45,010) and \$3,183 (\$938 \( \) \$11,250) in payments; 20.5 (41.6) and  $6.0 (2.0 \square 19.0)$  in payment cases; and 5.6 (5.2) and 4.0 $(2.0 \square 8.0)$  in number of pharmaceutical companies per specialist. (Table 1) Regarding the payment distribution, although 34.6% of specialists had no payments, 5.1% and 2.7% received more than \$50,000 and \$100,000, respectively. The Gini index for the four-year cumulative payments per specialist was 0.86. Top 1%, 5%, 10% and 25% of the specialists occupied 26.3% (95% confidence interval (CI):  $21.4\% \square 31.2\%$ ), 61.5% (95% CI: 57.0% \( \) 65.9%), 77.2% (95% CI: 73.9% \( \) 80.4%), and 93.6% (95% CI: 92.5% \( \Bigcirc 94.7\) of total payments, respectively. (Supplemental Material 2) One specialist received a maximum of \$711,965 payments over the four-year from 21 pharmaceutical companies. Of 18 executive members of the Association as of November 2021, 17 (94.4%) had

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

certification of infectious disease specialists. All the 17 members with the specialist certification, including the current Association president, received more substantial payments averaging \$163,792 (SD: \$173,475; median: \$95,551; IQR: \$54,227 \(\subseteq \) \$207,948) than the specialists without executive board membership (p<0.001 in Mann-Whitney U test) over the four-year. Payment trend between 2016 and 2019 The average annual payments per specialist ranged from \$5,775 (SD: \$13,410) in 2017 to \$6,134 (SD: \$15,283) in 2016, and median payments were from \$1,430 (IQR:  $511 \Box 4,531$ ) in 2017 to 1,737 (IQR:  $442 \Box 5,286$ ) in 2018. The payment values per specialist remained constant, with an average annual change of -1.2% (95% CI: -4.7%  $\square$  2.3%, p=0.49). The prevalence of specialists with payments decreased by -1.3% (95% CI:  $-2.9 \,\Box\, 0.4$ , p=0.13) in each year from 47.1% (760 out of 1614) in 2016 to 44.9% (724 out of 1614) in 2019, but were not statistically significant (p=0.12). Among 78 companies making payments, 10 companies were devoid of the four-year continuous payment data. Excluding payments from ten companies, the specialists received payments averaging from \$5,562 (SD: \$13,383) in 2017 to \$6,105 (SD:

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

\$13,312) in 2018. There were also no statistically significant annual changes in payments per specialist (average annual change rate: -1.3% [95% CI: -4.7 \( \triangle 2.3\) \( \triangle 1.3\) p=0.48) and prevalence of specialists with payments (average annual change rate: -1.4% [95% CI:  $-3.1\% \square 0.2\%$ ], p=0.093) between 2016 and 2019. (Table 2) Payment by pharmaceutical companies The top companies made 63.8% of the total payments, representing \$11,340,870 and 13,247 cases. (Figure 1) In company level analysis, the average and median number of specialists with payments per company were 74.9 (SD: 98.8) and 27.0 (IQR: 5.0-113.0), respectively. The average payments and number of cases per specialist were \$2,333 (SD: \$2,578) and 2.8 (SD: 1.9) cases, respectively. In short, each company made an average of \$2,333 payments, entailing 2.8 cases per specialist, to 74.9 specialists in average for the reimbursement of lecturing, consulting and writing. MSD made the largest payments of \$2,493,244 to 460 (28.5%) specialists. Pfizer with the second largest payments distributed a total of \$1,376,045 payments to 267 (16.5%) infectious specialists. The average payments per specialist were the highest from FujiFilm Toyama Chemical (\$7,269), followed by MSD (\$5,456), Pfizer (\$5,154), Boehringer Ingelheim (\$5,002), and AstraZeneca (\$4,990). Payment categories by each

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

company were described in Supplemental Material 3. MSD also had the largest number of drugs with new and additional indications (8 drugs), followed by Daiichi Sankyo Company (5 drugs) and GlaxoSmithKline (5 drugs). (Supplemental Material 4) There were moderately positive correlations between number of new or additional indications and (1) total payments (r(76)=0.46, p<0.001) and (2) number of specialists with payments (r(76)=0.43, p<0.001). Geographical payment distribution There were geographical differences in distribution of infectious disease specialists. (Supplemental Material 5A and 5B) Number of infectious disease specialists per million populations ranged from 0.8 in Iwate Prefecture to 47.9 in Nagasaki Prefecture, while the average number of specialists per million was 12.7 in nationwide. There were geographic differences in total and per-specialist payment distribution as well. (Supplemental Material 5C and 5D) The average payment values per specialist were the highest in Okayama Prefecture (\$21,750) and lowest in Ibaraki Prefecture (\$1,574). In the analysis by region, the number of specialists per million populations ranged from 7.8 in the Hokkaido region (northernmost of Japan), and 8.7 in the Tohoku region (northernmost of main Japanese islands) to 20.6 in the Kyusyu region (southernmost of

Japan). Meanwhile, the average payments per specialist were the highest in Tohoku

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

region (\$15,057), followed by Chugoku (the western part of main Japanese islands, \$13,980) and Kyusyu regions (\$13,394). **Discussion** This study demonstrated that a total \$17,717,264 personal payments, equal to 1.8% of all payments were distributed to the board-certified infectious disease specialists over the period of four years in Japan. Among all Japanese board-certified infectious disease specialists, 65.4% (1,055 out of 1,614) of the specialists received an average of \$16,794 and a median of \$3,183 personal payments from 78 pharmaceutical companies between 2016 and 2019. The payments per specialist and proportion of specialists with at least one payment remained stable between 2016 and 2019. First, this study found that there were substantial financial relationships among the board-certified infectious disease specialists and pharmaceutical companies in Japan. Although the prevalence of specialists with payments were similar to the previous findings, ranging from 62.0% among hematologists to 70.6% among medical oncologists[3, 4, 15, 23], payment values per specialist among the infectious disease

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

specialists (\$3,183 in median four-year combined payments and \$1,430-\$1,720 in median single-year payments) were higher than all of the available evidence among pediatric oncologists (\$2,961 in average)[23], pulmonologists (\$2,210 in median)[3], hematologists (\$2,471 in median)[23], and medical oncologists (\$1,103 in one-year median)[15] in Japan. Overall, compared to the previous studies, Japanese infectious disease specialists have higher financial relationships with pharmaceutical companies. Second, we found that the payment values and prevalence of specialists with payments did not significantly change between 2016 and 2019. Kusumi et al. found that the pharmaceutical companies increasingly prioritized the payments to hematologists in Japan, with a 11.2% annual increase in payments per specialist.[4] Also, similar trends were observed by Murayama et al. among Japanese pulmonologists, with 7.8% annual increase in payments.[3] Our finding was different from these studies, indicating that the financial relationships among infectious disease specialists and pharmaceutical companies did not decline nor increase, but remained stable for the last four years. Although we found that there were many drugs newly approved or gained additional indications for infectious diseases, the Japanese government now recommends physicians to refrain from using new antibiotics to prevent antimicrobial-resistant

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

bacteria. This trend in payments might be due to the demand for fewer use of new antibiotics. Furthermore, we found that vast majority of payments disproportionately concentrated only on a small portion of the infectious disease specialists in Japan. Surprisingly, a small portion of the specialists included authoritative specialists such as leaders of the Association and other medical societies. For example, the specialist with the largest payments (\$711,965) was in various authoritative positions such as a full professor at a private medical university and a very influential television commentator for infectious disease.[11] Also, he was the current executive member of the Association and other medical societies. The specialist with the second-largest payments (\$421,678) was also in authoritative positions such as a full professor at a national university and an executive or council member at several medical societies, including the Association, and the Japanese Respiratory Society. He also served on public authorities as an author of the clinical guidelines for COVID-19 issued by the Japanese Ministry of Health, Labor and Welfare[7] and as a member of government scientific advisory committee. The specialist with the fourth largest payments (\$318,565) was the former president of

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

the Association who served from 2017 to 2020. He was also a current executive member of the Association and the deputy chairperson of the Japanese government COVID-19 scientific advisory board, but his COI was not publicly disclosed by neither the Association nor the Japanese government.[10] The receipt of substantial personal payments by executive members of medical societies was widely prevalent in Japan and other countries such as the US. Saito et al. found that 86.9% of Japanese executive members received a median of \$7,486 personal payments in 2016, and especially members specialized in internal medicine had higher financial relationships with pharmaceutical companies. [24] Moynihan et al. elucidated that 72% of the US influential medical society leaders had financial ties with pharmaceutical companies, [25] and that 93% of the leaders of Infectious Diseases Society of America received \$31,805 in median total payments for six years, where the payments were the most prevalent of ten influential medical societies in the US.[25] Although we did not evaluate financial relationships during the tenure of the board membership, our findings indicated that the current board members of Japanese Association for Infectious Diseases had much larger financial relationships with pharmaceutical companies over the past several years, with 3.2 times higher median annual payments than those among

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

board members of other Japanese medical societies or at least 4.5 times higher median annual payment values than that of the Infectious Diseases Society of America. A number of studies have shown that financial relationships with pharmaceutical companies influence physicians' behavior in prescribing drugs, [26-30] recommending clinical guidelines, [5, 8, 31-33] and commenting on drugs in pharmaceutical advisory committees.[34-37] Pharmaceutical companies sometimes spend more payments for marketing less effective and less advantageous drugs[38, 39] but with more harms to patients.[40, 41] Despite these influences, the trends of the physicians' acceptance of personal payments from industries are still common[17, 42, 43] and are even increasing in several specialties.[3, 4, 23, 44] More transparency is required to reduce the undue influences of financial relationships with pharmaceutical companies on physician behaviors and potentially patients care, [28, 45] to increase trust in healthcare, and to provide patients with more information about their treatment.[46-49] However, there is no consensus on how to manage the financial relationships, and how to increase independency of healthcare professionals toward their primary interest of treating patients based on their best knowledge and conscience. [50] Restriction of these personal payments to the specialists to a certain degree would be a simple and reasonable

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

solution, but it is equally hard to implement by the professional medical societies when many of the society board members and societies themselves are financially tied to pharmaceutical companies. In the case of the Association, financial COIs self-declared by the board members were not publicly disclosed, and there was no restriction of the financial relationships among pharmaceutical companies and the board-certified specialists as of now. This analysis has few limitations. As we previously noted, our manual collection of payment data from 92 pharmaceutical companies' webpages might have included unavoidable human errors, despite our careful cross-checks to exclude duplicate physicians from the data. Second, currently, pharmaceutical companies do not disclose their payments concerning meals, beverages, accommodations, travel and stock ownerships, according to the JPMA guidance. This could have underestimated the extent and prevalence of overall financial relationships among the specialists and industries. Third, the data disclosed by the Association and pharmaceutical companies did not provide us many of detailed demographics of the specialists such as the specialists' gender, affiliation characteristics, positions within their affiliations, and their academic and clinical performances. Therefore, there would have been influence of

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

many unavoidable confounders on the personal payments at individual specialist level. However, our robust statistical analysis with GEE modeling has helped nullify effects of such confounders to some extent. Still, further studies should have elucidated the relations among the specialists' characteristics and the personal payments. Finally, this study was based on the open-access payment data and Japanese board-certified infectious disease specialists. Thus, the payment magnitude and trend may not be exactly replicable to other countries' specialists. However, this might serve as a pathway for prospective researchers to explore the same in other countries as well. Conclusion The majority of the certified infectious disease specialists received substantial personal payments for the reimbursements of lecturing, consulting and writing from the pharmaceutical companies in Japan. These financial relationships with those companies remained stable for the past four years in Japan. Furthermore, high ranked specialists such as those in the executive board had stronger financial ties with the companies. Such personal payments must be restricted to a certain level to avoid potential conflict of interest.

434 Acknowledgment 435 The authors thank the Tansa (formerly known as Waseda Chronicle) for providing 436 payment data. Also, we appreciate Mr. Souto Nagano, an undergraduate student from the Faculty of Letters, University of Tokyo; Mr. Kohki Yamada, a medical student at the 437 438 Osaka University School of Medicine; Mr. Takuto Sakaemura, an undergraduate student 439 from Faculty of Applied Science, Simon Fraser University; and Ms. Megumi Aizawa, a 440 graduate student from the Department of Industrial Engineering and Economics, School 441 of Engineering, Tokyo Institute of Technology, for their dedicated contributions on 442 collecting and cross-checking the payment data. 443 444 References 445 1. Agrawal S, Brennan N, Budetti P. The Sunshine Act--effects on physicians. N Engl J Med 2013; 446 368(22): 2054-7. 447 2. Pham-Kanter G. Act II of the Sunshine Act. PLoS Med 2014; 11(11): e1001754. 448 3. Murayama A, Hoshi M, Saito H, et al. Nature and Trends of Pharmaceutical Payments to Board 449 Certificated Respiratory Specialists in Japan between 2016 and 2019. medRxiv 2022: 450 2022.01.16.22269188. 451 4. Kusumi E, Murayama A, Kamamoto S, et al. Pharmaceutical Payments to Japanese Certificated 452 Hematologists: A Retrospective Analysis of Personal Payments from Pharmaceutical Companies 453 between 2016 and 2019. medRxiv 2022: 2022.01.17.22269284. 454 5. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial and Intellectual 455 Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis. 456 Otolaryngol Head Neck Surg 2021; 0(0): 1945998211034724. 457 6. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T. Pharmaceutical company 458 payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment. Liver International 2021; 41(3): 464-9. 459

- 460 7. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A. Evaluation of Financial
- 461 Conflicts of Interest and Drug Statements in the Coronavirus Disease 2019 Clinical Practice
- Guideline in Japan. Clin Microbiol Infect **2021**.
- 463 8. Johnson L, Stricker RB. Attorney General forces Infectious Diseases Society of America to redo
- Lyme guidelines due to flawed development process. J Med Ethics **2009**; 35(5): 283-8.
- Saito H, Tani Y, Ozaki A, et al. Financial ties between authors of the clinical practice guidelines
- and pharmaceutical companies: an example from Japan. Clin Microbiol Infect **2019**; 25(11):
- 467 1304-6.
- 468 10. Mamada H, Murayama A, Ozaki A, et al. Financial and Non-financial Conflicts of Interest
- Among the Japanese Government Advisory Board Members Concerning Coronavirus Disease
- 470 2019. medRxiv **2021**.
- 471 11. Murayama A, Ozaki A, Saito H, Sawano T, Sah R, Tanimoto T. Coronavirus disease 2019
- 472 experts appearing on Japanese television: their characteristics and financial conflicts of interest
- with pharmaceutical companies. Clinical Microbiology and Infection 2020.
- 474 12. Koike S, Matsumoto M, Ide H, Kawaguchi H, Shimpo M, Yasunaga H. Internal medicine board
- 475 certification and career pathways in Japan. BMC Medical Education 2017; 17(1): 83.
- 476 13. Pharmaceuticals and Medical Devices Agency. List of approved products. Available at:
- 477 <a href="https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html">https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html</a>.
- 478 Accessed Februay 24.
- 479 14. Murayama A, Ozaki A, Saito H, et al. Pharmaceutical company payments to dermatology
- Clinical Practice Guideline authors in Japan. PLoS One **2020**; 15(10): e0239610.
- 481 15. Ozaki A, Saito H, Onoue Y, et al. Pharmaceutical payments to certified oncology specialists in
- Japan in 2016: a retrospective observational cross-sectional analysis. BMJ Open **2019**; 9(9):
- 483 e028805.
- 484 16. Saito H, Ozaki A, Sawano T, Shimada Y, Tanimoto T. Evaluation of Pharmaceutical Company
- 485 Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline
- 486 Authors in Japan. JAMA Netw Open **2019**; 2(4): e192834.
- 487 17. Tarras ES, Marshall DC, Rosenzweig K, Korenstein D, Chimonas S. Trends in Industry
- 488 Payments to Medical Oncologists in the United States Since the Inception of the Open Payments
- 489 Program, 2014 to 2019. JAMA Oncology **2021**; 7(3): 440-4.
- 490 18. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and
- Distribution of Payments From Industry to Physicians in 2015. JAMA 2017; 317(17): 1774-84.
- 492 19. Tringale KR, Hattangadi-Gluth JA. Types and Distributions of Biomedical Industry Payments to
- Men and Women Physicians by Specialty, 2015. JAMA Intern Med 2018; 178(3): 421-3.
- 494 20. Feng H, Wu P, Leger M. Exploring the Industry-Dermatologist Financial Relationship: Insight
- From the Open Payment Data. JAMA Dermatol **2016**; 152(12): 1307-13.

- 496 21. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial conflicts of
- interest between pharmaceutical companies and the authors of urology clinical practice
- 498 guidelines in Japan. Int Urogynecol J **2021**; 32(2): 443-51.
- 499 22. Ozieranski P, Csanadi M, Rickard E, Tchilingirian J, Mulinari S. Analysis of Pharmaceutical
- Industry Payments to UK Health Care Organizations in 2015. JAMA Netw Open **2019**; 2(6):
- 501 e196253.
- 502 23. Kusumi E, Murayama A, Kamamoto S, et al. Pharmaceutical Payments to Japanese Certificated
- 503 Pediatric Hematologist/Oncologists: a cross-sectional analysis of personal payments from
- 504 pharmaceutical companies between 2016 and 2019. Authorea Preprints 2022.
- 505 24. Saito H, Ozaki A, Kobayashi Y, Sawano T, Tanimoto T. Pharmaceutical Company Payments to
- 506 Executive Board Members of Professional Medical Associations in Japan. JAMA Intern Med
- **2019**; 179(4): 578-80.
- 508 25. Moynihan R, Albarqouni L, Nangla C, Dunn AG, Lexchin J, Bero L. Financial ties between
- 509 leaders of influential US professional medical associations and industry: cross sectional study.
- 510 BMJ **2020**; 369: m1505.
- Perlis RH, Perlis CS. Physician Payments from Industry Are Associated with Greater Medicare
- Part D Prescribing Costs. PLOS ONE **2016**; 11(5): e0155474.
- 513 27. DeJong C, Aguilar T, Tseng C-W, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical Industry-
- 514 Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. JAMA Internal
- 515 Medicine **2016**; 176(8): 1114-22.
- 516 28. Mitchell AP, Trivedi NU, Gennarelli RL, et al. Are Financial Payments From the Pharmaceutical
- Industry Associated With Physician Prescribing?: A Systematic Review. Ann Intern Med **2020**.
- 518 29. Goupil B, Balusson F, Naudet F, et al. Association between gifts from pharmaceutical companies
- 519 to French general practitioners and their drug prescribing patterns in 2016: retrospective study
- 520 using the French Transparency in Healthcare and National Health Data System databases. BMJ
- **2019**: 367: 16015.
- 522 30. Inoue K, Figueroa JF, DeJong C, et al. Association Between Industry Marketing Payments and
- 523 Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the
- United States. Circulation: Cardiovascular Quality and Outcomes **2021**; 14(5): e007521.
- 525 31. Nejstgaard CH, Bero L, Hrobjartsson A, et al. Association between conflicts of interest and
- 526 favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces,
- and narrative reviews: systematic review. BMJ **2020**; 371: m4234.
- 528 32. Coyne DW. Influence of Industry on Renal Guideline Development. Clinical Journal of the
- 529 American Society of Nephrology **2007**; 2(1): 3-7.
- 530 33. Steinbrook R. Guidance for guidelines. N Engl J Med 2007; 356(4): 331-3.
- 531 34. Arthur W, Austin J, Wayant C, Vassar M. Association of Conflicts of Interest for Public Speakers

- for the Peripheral and Central Nervous System Drugs Advisory Committee of the US Food and
- Drug Administration With Their Statements. JAMA Neurology **2019**; 76(3): 368-9.
- 534 35. Bickford T, Kinder N, Arthur W, Wayant C, Vassar M. The Potential Effects of Financial
- 535 Conflicts of Interest of Speakers at the US Food and Drug Administration's Pulmonary-Allergy
- Drug Advisory Committee Meetings. Chest **2021**; 159(6): 2399-401.
- 537 36. Johnson BS, Roberts W, Riddle J, Wayant C, Scott J, Vassar M. Potential Financial Bias From
- Speakers at US Food and Drug Administration's Bone, Reproductive, and Urologic Drugs
- Advisory Committee Meetings. Urology **2020**; 137: 1-6.
- 540 37. Cooper CM, Jellison S, Vassar M. Characteristics of Open Public Hearing Speakers of the
- 541 Tobacco Products Scientific Advisory Committee meetings. Tob Prev Cessat 2018; 4: 35-.
- 542 38. Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?
- 543 Bmj **2017**; 357: j1855.
- 544 39. Lexchin J. The relation between promotional spending on drugs and their therapeutic gain: a
- 545 cohort analysis. CMAJ Open **2017**; 5(3): E724-e8.
- 546 40. Eichacker PQ, Natanson C, Danner RL. Surviving Sepsis Practice Guidelines, Marketing
- 547 Campaigns, and Eli Lilly. New England Journal of Medicine 2006; 355(16): 1640-2.
- 548 41. Mitchell AP, Winn AN, Dusetzina SB. Pharmaceutical Industry Payments and Oncologists'
- 549 Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Intern Med 2018;
- 550 178(6): 854-6.
- 551 42. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in Industry
- 552 Payments to Physicians in the United States From 2014 to 2018. JAMA 2020; 324(17): 1785-8.
- 553 43. Ahlawat A, Narayanaswami P. Financial relationships between neurologists and industry.
- Neurology **2019**; 92(21): 1006.
- 555 44. Putman MS, Goldsher JE, Crowson CS, Duarte-García A. Industry Payments to Practicing US
- 556 Rheumatologists, 2014–2019. Arthritis & Rheumatology **2021**; 73(11): 2138-44.
- 557 45. Ozaki A, Murayama A, Saito H, et al. Transparency Is Not Enough: How Can We Improve the
- 558 Management of Financial Conflicts of Interest Between Pharma and Healthcare Sectors? Clin
- 559 Pharmacol Ther **2020**.
- 560 46. Kanter GP, Carpenter D, Lehmann LS, Mello MM. US Nationwide Disclosure of Industry
- Payments and Public Trust in Physicians. JAMA Network Open **2019**; 2(4): e191947-e.
- 562 47. Lopez J, Naved BA, Pradeep T, et al. What Do Plastic Surgery Patients Think of Financial
- Conflicts of Interest and the Sunshine Act? Annals of Plastic Surgery **2019**; 82(6): 597-603.
- 564 48. Kanter GP, Carpenter D, Lehmann L, Mello MM. Effect of the public disclosure of industry
- payments information on patients: results from a population-based natural experiment. BMJ
- 566 Open **2019**; 9(2): e024020.
- 567 49. Stein GE, Kamler JJ, Chang JS. Ophthalmology Patient Perceptions of Open Payments

Information. JAMA Ophthalmology **2018**; 136(12): 1375-81.

Moynihan R, Bero L, Hill S, et al. Pathways to independence: towards producing and using trustworthy evidence. BMJ **2019**; 367: l6576.

trustworthy evidence. BMJ **2019**; 367: l6576.

Table 1. Summary of personal payments from Japanese pharmaceutical companies to infectious disease specialists certified by the Japanese Association for Infectious Disease between 2016 and 2019

Variables					
Total					
Payment values, US\$	17,784,070				
Cases, n	21,680				
Companies, n	78				
Average per specialist (SD)					
Payment values, US\$	16,857 (45,010)				
Cases, n	20.5 (41.6)				
Companies, n	5.6 (5.2)				
Median per specialist (IQR)					
Payment values, US\$	$3,183 (938 \square 11,250)$				
Cases, n	$6.0\ (2.0\square19.0)$				
Companies, n	$4.0 (2.0 \square 8.0)$				
Range					
Payment values, US\$	31 □ 711,965				
Cases, n	1.0□ 538.0				
Companies, n	$1.0 \square 29.0$				
Physicians with specific payments, n (%)					
Any payments	1,055 (65.4)				
Payments >US\$500	930 (57.6)				
Payments >US\$1,000	776 (48.1%)				
Payments >US\$5,000	419 (26.0)				
Payments >US\$10,000	290 (18.0)				
Payments >US\$50,000	82 (5.1)				
Payments >US\$100,000	43 (2.7)				
Gini index	0.857				
Category of payments					
Lecturing					
Payment value, US\$ (%)	14,607,478 (82.1)				
Cases, n (%)	18,078 (83.1)				
Consulting					
Payment value, US\$ (%)	1,981,003 (11.1)				
Cases, n (%)	2,122 (9.8)				
Writing					
Payment value, US\$ (%)	797,929 (4.5)				
Cases, n (%)	1,086 (5.0)				
Other					
Payment value, US\$ (%)	397,659 (2.2)				
Cases, n (%)	459 (2.1)				

Table 2. Trends of personal payments from Japanese pharmaceutical companies to infectious disease specialists certified by the Japanese Association for Infectious Disease between 2016 and 2019

Variables	2016	2017	2018	2019	Average yearly change (95%CI), %	p-value	Combined total
All pharmaceutical companies							
Total payments, US\$	4,662,217	4,215,566	4,538,520	4,367,767			17,78,4070
Average payments (SD), US\$	6,134 (15,283)	5,775 (13,410)	6,108 (13,324)	6,033 (11,837)	-1.2 (-4.7 □2.3)	0.49	16,857 (45,010)
Median payments (IQR), US\$	$1,604 (511 \square 4,646)$	$1,430 (511 \square 4,531)$	1,737 (642- □5,286)	1,554 (662- □5,258)			3,183 (938 🗆 11,250)
Payment range, US\$	92 \( 216,035	92 □ 160,610	95 □ 190,726	31 🗆 144,593			31 □ 711,965
Physicians with specific payments, n (%)							
Any payments	760 (47.1%)	730 (45.2%)	743 (46.0%)	724 (44.9%)	$-1.3 (-2.9 \square 0.4)$	0.13	1,055 (65.4%)
Payments >US\$500	612 (37.9%)	594 (36.8%)	628 (38.9%)	616 (38.2%)	$0.8 (-1.1 \square 2.6)$	0.43	930 (57.6%)
Payments >US\$1,000	482 (29.9%)	436 (27.0%)	485 (30.0%)	453 (28.1%)	$-0.8 (-2.9\% \square 1.3)$	0.45	776 (48.1%)
Payments >US\$5,000	175 (10.8%)	178 (11.0%)	193(12.0%)	187 (11.6%)	$2.8 (-0.8 \square 6.5)$	0.13	419 (26.0%)
Payments >US\$10,000	106 (6.6%)	94 (5.8%)	113 (7.0%)	103 (6.4%)	$1.0 (-3.6 \square 5.7)$	0.68	290 (18.0%)
Payments >US\$50,000	16 (1.0%)	14 (0.9%)	17 (1.1%)	14 (0.9%)	-1.9 (-15.9 $\square$ 14.3)	0.80	82 (5.1%)
Payments >US\$100,000	4 (0.2%)	3 (0.2%)	1 (0.1%)	2 (0.1%)	-28.3 (-52.4□8.1)	0.11	43 (2.7%)
Gini index	0.878	0.881	0.870	0.876			0.860
Pharmaceutical companies with four-year payment data <sup>a</sup>							
Total payments, US\$	4,597,653	4,205,920	4,492,988	4,314,421			17,610,982
Average payments (SD), US\$	6,074 (15,169)	5,562 (13,383)	6,105 (13,312)	5,992 (12,825)	-1.3 (-4.7 □ 2.3)	0.48	16,788 (44,820)
Median payments (IQR), US\$	$1,603 (511 \square 4,642)$	1,430 (511- □4,525)	1,737 (613- □5,280)	1,552 (662- □5,258)			3,183 (920 🗆 11,238)
Payment range, US\$ Physicians with specific payments, n (%)	92□215,089	92 🗆 160,610	92 🗆 190,726	31 🗆 143,571			31 🗆 709,997
Any payments	757 (46.9)	730 (45.3)	736 (45.6)	720 (44.6)	-1.4 (-3.1 □ 0.2)	0.093	1,049 (65.0)
Payments >US\$500	609 (37.7)	593 (36.7)	620 (38.4)	610 (37.8)	$0.5 \ (-1.4 \square 2.4)$	0.60	927 (57.4)
Payments >US\$1,000	478 (29.6)	436 (27.0)	481 (29.8)	452 (28.0)	-0.7 (-2.8 🗆 1.4)	0.51	768 (47.6)
Payments >US\$5,000	172 (10.7)	179 (11.1)	191 (11.8)	186 (11.5)	3.1 (-0.6 \( \text{6.8} \)	0.10	415 (25.7)
Payments >US\$10,000	106 (6.6)	94 (5.8)	112 (7.1)	103 (6.4)	0.9 (-3.7 \( \times 5.6 \)	0.71	289 (17.9)
Payments >US\$50,000	14 (0.9)	14 (0.9)	17 (1.1)	14 (0.9)	$0.0 \ (-13.7 \square 15.9)$	1.0	82 (5.1)

Payments >US\$100,000	4 (0.2)	3 (0.2)	1 (0.1)	2 (0.1)	-28.3 (-52.4□8.1)	0.11	42 (2.6)
Gini index	0.879	0.881	0.871	0.876			0.860
IQR:	interquartile	ran	ge;	SD:	standaro	i	deviation







Figure 1.Total payment by company





38

Supplemental Material 3. Payment category by company



Brand name	Name	Pharmaceutical companies	Approval date	Price per drug unit, US\$*	Indication	Category
ZERBAXA	Ceftolozane sulfate/Tazobactam sodium	Manufacturer and distributor: MSD K. K	December 20, 2019	\$59 (1.5g/bottle)	Treatment of sepsis and pneumonia caused by Serratia and Hemophilus influenza	Additional indication
LASVIC	Lascufloxacin hydrochloride	Manufacturer and distributor: Kyorin Pharmaceuticals	September 20, 2019	\$3 (75mg/pill) \$37 (150mg/ intravenous infusion kit)	Treatment of laryngopharyngitis, tonsillitis, acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media and sinusitis	New approval
MAVIRET	Glecaprevir hydrate/Pibrentasvir	Manufacturer and distributor: AbbVie GK	August 22, 2019	\$168/pill	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C	Additional indication
AZIMYCIN	Azithromycin hydrate	Manufacturer and distributor: Senju Pharmaceuticals Distributor: Takeda Pharmaceutical	June 18, 2019	\$3 (1%1ml eye-drops)	Treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis	New approval
SYMTUZA	Darunavir ethanolate/Cobicistat /Emtricitabine/Tenofovir alafenamide fumarate	Manufacturer and distributor: Janssen Pharmaceutical K. K	June 18, 2019	\$44/pill	Treatment of HIV-1 infection	New approval
INAVIR	Laninamivir octanoate hydrate	Manufacturer and distributor: Daiichi Sankyo	June 18, 2019	\$20 (20mg/inhalation kit) \$39 (160mg/bottle)	Treatment of influenza A or B virus infection	New approval
GENVOYA	Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide fumarate	Manufacturer and distributor: Gilead Sciences	May 22, 2019	\$65/pill	Treatment of HIV-1 infection	Additional indication
BIKTARVY	Bictegravir sodium/ Emtricitabine/Tenofovir alafenamide fumarate	Manufacturer and distributor: Gilead Sciences	March 26, 2019	\$65/pill	Treatment of HIV-1 infection	New approval
ZERBAXA	Ceftolozane sulfate/Tazobactam sodium	Manufacturer and distributor: MSD K. K	January 8, 2019	\$59 (1.5g/bottle)	Treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis and liver abscess	New approval
EPCLUSA	Sofosbuvir/Velpatasvir	Manufacturer and distributor: Gilead Sciences	January 8, 2019	\$562/pill	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who have previously been treated.  Improvement of viremia in patients with decompensated cirrhosis type C	New approval
REBETROL	Ribavirin	Manufacturer and distributor: ViiV Healthcare Distributor: GlaxoSmithKline K. K Promotional partner: Shionogi	January 8, 2019	\$4 (200mg)	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who have previously been treated	Additional indication
JULUCA	Dolutegravir sodium/Rilpivirine hydrochloride	Manufacturer and distributor: ViiV Healthcare	November 26, 2018	\$50/pill	Treatment of HIV-1 infection	New approval

		Distributor: GlaxoSmithKline K. K				
ODEFSEY	Rilpivirine hydrochloride /Emtricitabine/Tenofovir alafenamide fumarate	Manufacturer and distributor: Janssen Pharmaceutical K. K	August 21, 2018	\$56/pill	Treatment of HIV-1 infection	New approval
ISENTRESS	Raltegravir potassium	Manufacturer and distributor: MSD K. K	May 14, 2018	\$15 (400mg/pill) \$15 (600mg/pill)	Treatment of HIV infection	New approval
KAKETSUKEN	Emulsion-adjuvanted cell- culture derived influenza HA vaccine (H5N1)	Manufacturer and distributor: The Chemo-Sero-Therapeutic Research Institute	March 23, 2018	NA	Prevention of pandemic influenza (H5N1)	Additional indication
KAKETSUKEN	Emulsion-adjuvanted cell- culture derived influenza HA vaccine (prototype)	Manufacturer and distributor: The Chemo-Sero-Therapeutic Research Institute	March 23, 2018	NA	Prevention of pandemic influenza	Additional indication
XOFLUZA	Baloxavir marboxil	Manufacturer and distributor: Shionogi	February 23, 2018	\$14 (10mg/pill) \$22 (20mg/pill)	Treatment of influenza A or B virus infections	New approval
HARVONI	Ledipasvir acetonate/Sofosbuvir	Manufacturer and distributor: Gilead Sciences	February 16, 2018	\$509/pill	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2	Additional indication
ZINPLAVA	Bezlotoxumab	Manufacturer and distributor: MSD K. K	September 27, 2017	\$3081 (625mg/25ml bottle)	Prevention of recurrent Clostridium difficile infection	New approval
MAVIRET	Glecaprevir hydrate/ Pibrentasvir	Manufacturer and distributor: AbbVie GK	September 27, 2017	\$168/pill	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C	New approval
TAMIFLU	Oseltamivir phosphate	Manufacturer and distributor: Chugai Pharmaceutical	March 24, 2017	\$2 (75mg/pill) \$2 (3%/g dry syrup)	Treatment of influenza A or B virus infection	Additional indication
SOVALDI	Sofosbuvir	Manufacturer and distributor: Gilead Sciences	March 24, 2017	\$395 (400mg/pill)	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in neither Serogroup 1 (genotype 1) nor Serogroup 2 (genotype 2)	Additional indication
REBETOL	Ribavirin	Manufacturer and distributor: MSD K. K	March 24, 2017	\$4 (200mg/pill)	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in neither Serogroup 1 (genotype 1) nor Serogroup 2 (genotype 2)	Additional indication
OZEX	Tosufloxacin tosilate hydrate	Manufacturer and distributor: Fujifilm Toyama Chemical	March 2, 2017	\$1.1 (60mg/pill) \$0.5 (75mg/pill) \$0.6 (150mg/pill) \$1.2 (0.3%/ml eyedrops)	Treatment of mycoplasma pneumonia caused by Mycoplasma pneumoniae	Additional indication
RIAMET	Artemether/Lumefantrine	Manufacturer and distributor: Novartis Pharma K. K	December 19, 2016	\$2/pill	Treatment of malaria	New approval
VAXEM HIB	Hemophilus influenzae type b vaccine adsorbed	Manufacturer and distributor: Takeda Pharmaceutical	December 19, 2016	NA	Prophylaxis of Hemophilus influenzae type b infections	Additional indication
XIMENCY	Daclatasvir hydrochloride/ Asunaprevir/Beclabuvir hydrochloride	Manufacturer and distributor: Bristol Myers Squibb	December 19, 2016	\$99/pill	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1)	New approval

DESCOVY	Emtricitabine/ Tenofovir alafenamide fumarate	Manufacturer and distributor: Gilead Sciences	December 9, 2016	\$26/pill (LT) \$37/pill (HT)	Treatment of HIV-1 infection	New approval
PREZCOBIX	Darunavir ethanolate/ Cobicistat	Manufacturer and distributor: Janssen Pharmaceutical K. K	November 22, 2016	\$19	Treatment of HIV infection	New approval
ERELSA	Elbasvir	Manufacturer and distributor: MSD K. K	September 28, 2016	\$223 (50mg/pill)	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1)	New approval
VIEKIRAX	Ombitasvir hydrate/ Paritaprevir hydrate/ Ritonavir	Manufacturer and distributor: AbbVie GK	September 28, 2016	\$204/pill	Improvement of viremia in patients with chronic hepatitis C in serogroup 2 (genotype 2)	Additional indication
GRAZYNA	Grazoprevir hydrate	Manufacturer and distributor: MSD K. K	September 28, 2016	\$80 (50mg/pill)	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1)	New approval
REBETOL	Ribavirin	Manufacturer and distributor: MSD K. K	September 28, 2016	\$4 (200mg/capsule)	Improvement of viremia in patients with chronic hepatitis C in serogroup 2	Additional indication
INAVIR	Laninamivir octanoate hydrate	Manufacturer and distributor: Daiichi Sankyo	August 26, 2016	\$20 (20mg/inhalation kit) \$39 (160mg/bottle)	Prophylaxis of influenza A or B virus infections	Additional indication
GENVOYA	Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide fumarate	Manufacturer and distributor: Gilead Sciences	June 17, 2016	\$65/pill	Treatment of HIV-1 infection	New approval
MALARONE	Atovaquone/Proguanil hydrochloride	Manufacturer and distributor: GlaxoSmithKline K. K	March 28, 2016	\$5/pill (adult) \$2/pill (children)	Treatment and prevention of malaria	Additional indication
PRIMAQUINE	Primaquine phosphate	Manufacturer and distributor: Sanofi S.A.	March 28, 2016	\$21 (15mg/pill)	Treatment of malaria caused by Plasmodium vivax and P. ovale	New approval
BIKEN	Freeze-dried live attenuated varicella vaccine	Manufacturer and distributor: The Research Foundation for Microbial Diseases of Osaka University Distributor: Mitsubishi Tanabe Pharma Corporation	March 18, 2016	NA	Prevention of herpes zoster in individuals 50 years of age and older	Additional indication
KITASATO DAIICHI SANKYO	Adsorbed cell culture-derived influenza vaccine (H5N1)	Manufacturer and distributor: Daiichi Sankyo Distributor: Kitasato Pharmaceutical Industry	March 18, 2016	NA	Prevention of pandemic influenza (H5N1)	Additional indication
TRIBIK	Adsorbed diphtheria-purified pertussis-tetanus combined vaccine	Manufacturer and distributor: The Research Foundation for Microbial Diseases of Osaka University Distributor: Mitsubishi Tanabe Pharma Corporation	February 29, 2016	NA	Prevention of pertussis, diphtheria and tetanus	Additional indication
VAXEM HIB	Hemophilus influenzae type b	Manufacturer and distributor:	January 22,	NA	Prophylaxis of Hemophilus influenzae type b	New approval


	vaccine absorbed	Takeda Pharmaceutical	2016		infections	
REMICADE	Infliximab	Manufacturer and distributor: Mitsubishi Tanabe Pharma Corporation Distributor: Janssen Biotech	December 21, 2015	\$648(100mg bottle)	Treatment of acute-phase Kawasaki's disease in patients who have not responded sufficiently to conventional therapies	Additional indication
VIEKIRAX	Ombitasvir hydrate/Paritaprevir hydrate/Ritonavir	Manufacturer and distributor: AbbVie GK	September 28, 2015	\$204/pill	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1)	New approval
CIPROXAN	Ciprofloxacin	Manufacturer and distributor: Bayer Yakuhin	September 24, 2015	\$0.3 (100mg/pill) \$0.4 (200mg/pill) \$17 (200mg/100ml) \$21 (300mg/150ml) \$19 (400mg/200ml)	Treatment of sepsis, pneumonia, etc.	Additional indication
HARVONI	Ledipasvir acetonate/Sofosbuvir	Manufacturer and distributor: Gilead Sciences	July 3, 2015	\$509/pill	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1)	New approval
DIFLUCAN	Fluconazole	Manufacturer and distributor: Pfizer	May 26, 2015	\$3 (50mg capsule) \$4 (100mg capsule) \$17 (0.1% 50ml bottle) \$22 (0.2% 50ml bottle) \$36 (0.2% 100ml bottle)	Treatment of vaginitis and vulvovaginitis caused by Candida	Additional indication
ALDREB	Colistin sodium methanesulfonate	Manufacturer and distributor: GlaxoSmithKline K. K	March 26, 2015	\$77 (150mg bottle)	Treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa and Acinetobacter	New approval
SYNFLORIX	Pneumococcal 10-valent conjugate vaccine adsorbed	Manufacturer: GlaxoSmithKline K. K Distributor: Daiichi Sankyo	March 26, 2015	NA	Prophylaxis of pneumonia and pneumococcal invasive diseases	New approval
KAKETSUKEN	Cell culture-derived influenza emulsion HA vaccines (prototype)	Manufacturer and distributor: The Chemo-Sero-Therapeutic Research Institute	March 26, 2015	NA	Prevention of pandemic influenza	New approval
SOVALDI	Sofosbuvir	Manufacturer and distributor: Gilead Sciences	March 26, 2015	\$395 (400mg pill)	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2)	New approval
COPEGUS	Ribavirin	Manufacturer and distributor: Chugai Pharmaceutical	March 26, 2015	\$6 (200mg/pill)	Improvement of viremia with the concomitant use of sofosbuvir in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2)	Additional indication
DAKLINZA	Daclatasvir hydrochloride	Manufacturer and distributor: Bristol Myers Squibb	March 20, 2015	\$74 (60mg/pill)	Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1)	Changed approval
TRIUMEQ	Dolutegravir sodium, Abacavir sulfate, Lamivudine	Manufacturer and distributor: ViiV Healthcare	March 16, 2015	\$64/pill	Treatment of HIV infection	New approval

VENOGLOBULIN	Polyethylene glycol treated human normal immunoglobulin	Manufacturer and distributor: Japan Blood Products	February 2, 2015	\$347 (5g/100ml bottle) \$702 (10g/200ml bottle)	Prevention of acute otitis media, acute bronchitis, or pneumonia caused by Pneumococcus or	Additional indication
		Organization		, , , , , , , , , , , , , , , , , , ,	Hemophilus influenzae in patients associated with a decrease in serum IgG2 levels	

<sup>\*</sup>Price per drug was converted into US dollars using the 2019 average monthly exchange rates of ¥109.0 per \$1.

Price per drug was used as of February 19, 2022.

Drug price for vaccines was not determined and was open priced in Japan. So, it was not available.



Supplemental Material 5. Geographical characteristics of payment distribution

5A: The number of infectious disease specialists in 2021; 5B: The number of infectious disease specialists per million population in 2021; 5C: total personal payment values to the infectious disease specialists from 2016 to 2019; 5D: average personal payment values per infectious disease specialist from 2016 to 2019

